Education
About Us
Working with TipRanks
Follow Us
10x Genomics Inc (TXG)
NASDAQ:TXG
TXG Stock Chart & Stats
$13.59
-$0.12(-0.77%)
At close: 4:00 PM EST
$13.59
-$0.12(-0.77%)
Day’s Range― - ―
52-Week Range$6.78 - $18.21
Previous CloseN/A
Volume385.49K
Average Volume (3M)2.75M
Market Cap
$1.71B
Enterprise Value$1.08B
Total Cash (Recent Filing)$447.26M
Total Debt (Recent Filing)$86.74M
Price to Earnings (P/E)―
Beta1.71
Next Earnings
Nov 06, 2025EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.28
Shares Outstanding114,411,470
10 Day Avg. Volume2,810,198
30 Day Avg. Volume2,745,020
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.63
Enterprise Value/Revenue1.68
Enterprise Value/Gross Profit2.41
Enterprise Value/Ebitda-19.96
Forecast
1Y Price Target
$14.57Price Target Upside7.21% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
Bulls Say, Bears Say
Bulls Say
Business ModelThe business model exhibits compelling characteristics, mirroring a 'razor-and-blade' framework, providing a recurring revenue stream through high-margin consumables.
Innovation And GrowthInvestments in innovation, commercial infrastructure, and a global service network have cemented 10x Genomics' position as the gold standard.
Technological Leadership10x Genomics has the best offering in single cell with the largest install base and a technological lead vs. competitors.
Bears Say
Budget ConstraintsA significant portion of TXG's revenue comes from the US academic market, which faces budget constraints affecting overall demand.
Macroeconomic ChallengesThe macro environment remains challenging with external headwinds affecting the biopharma end-market and causing uncertainty in purchasing tools for discovery research.
Revenue Guidance Uncertainty10x Genomics withdrew its full-year guidance due to uncertain macroeconomic conditions and significant exposure to pressured end-markets.
10x Genomics News
TXG FAQ
What was 10x Genomics Inc’s price range in the past 12 months?
10x Genomics Inc lowest stock price was $6.78 and its highest was $18.21 in the past 12 months.
What is 10x Genomics Inc’s market cap?
10x Genomics Inc’s market cap is $1.71B.
When is 10x Genomics Inc’s upcoming earnings report date?
10x Genomics Inc’s upcoming earnings report date is Nov 06, 2025 which is in 8 days.
How were 10x Genomics Inc’s earnings last quarter?
10x Genomics Inc released its earnings results on Aug 07, 2025. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of -$0.37 by $0.65.
Is 10x Genomics Inc overvalued?
According to Wall Street analysts 10x Genomics Inc’s price is currently Undervalued.
Does 10x Genomics Inc pay dividends?
10x Genomics Inc does not currently pay dividends.
What is 10x Genomics Inc’s EPS estimate?
10x Genomics Inc’s EPS estimate is -0.29.
How many shares outstanding does 10x Genomics Inc have?
10x Genomics Inc has 114,411,470 shares outstanding.
What happened to 10x Genomics Inc’s price movement after its last earnings report?
10x Genomics Inc reported an EPS of $0.28 in its last earnings report, beating expectations of -$0.37. Following the earnings report the stock price went down -3.984%.
Which hedge fund is a major shareholder of 10x Genomics Inc?
Currently, no hedge funds are holding shares in TXG
10x Genomics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$14.57 (7.21% Upside)
$14.57 (7.21% Upside)
Blogger Sentiment
Neutral
TXG Sentiment 50%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 3.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $539.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.2%
Last 30 Days ▲ 12.4%
Last 30 Days ▲ 12.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-12.26%
12-Months-Change
Fundamentals
Return on Equity
-11.30%
Trailing 12-Months
Asset Growth
5.41%
Trailing 12-Months
Company Description
10x Genomics Inc
10x Genomics (TXG) is a biotechnology company specializing in genomic sequencing and analysis technologies that enable researchers to gain insights into complex biological systems. Founded in 2012 and headquartered in Pleasanton, California, the company operates primarily in the life sciences sector. Its core products include the Chromium System, which allows for high-throughput single-cell sequencing, and various reagents and software solutions designed for applications in genomics, transcriptomics, and epigenomics. 10x Genomics serves a diverse customer base including academic institutions, pharmaceutical companies, and biotechnology firms, facilitating advancements in precision medicine and personalized therapeutics.
TXG Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted a mix of positive developments, such as a favorable litigation settlement and growth in spatial consumables, alongside challenges like declining instrument revenue and a difficult funding environment. While there are areas of growth and strategic advancements, the ongoing challenges in the academic and CapEx environment present significant hurdles.View all TXG earnings summariesTXG Revenue Breakdown
60.32% Americas
22.99% EMEA
8.45% Asia-Pacific excluding China
8.24% China
TXG Stock 12 Month Forecast
Average Price Target
$14.57
▲(7.21% Upside)
Technical Analysis
Omnicell
―
Schrodinger
―
GeneDx Holdings
―
SOPHiA GENETICS
―
Hinge Health, Inc. Class A
―
Ownership Overview
2.31% Insiders
19.96% Mutual Funds
0.83% Other Institutional Investors
50.90% Public Companies and Individual Investors